SI-BONE (SIBN) Projected to Post Quarterly Earnings on Monday

SI-BONE (NASDAQ:SIBN - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data after the market closes on Monday, May 5th. Analysts expect SI-BONE to post earnings of ($0.24) per share and revenue of $45.13 million for the quarter. SI-BONE has set its FY 2025 guidance at EPS.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The firm had revenue of $49.00 million during the quarter, compared to analyst estimates of $48.87 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. On average, analysts expect SI-BONE to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SI-BONE Stock Up 2.3 %

NASDAQ:SIBN traded up $0.31 during trading hours on Friday, reaching $13.99. 355,356 shares of the company traded hands, compared to its average volume of 359,579. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The business's 50-day moving average price is $14.61 and its two-hundred day moving average price is $14.67. SI-BONE has a 1 year low of $11.70 and a 1 year high of $19.16. The stock has a market capitalization of $594.98 million, a P/E ratio of -15.21 and a beta of 0.82.

Insiders Place Their Bets

In related news, insider Anthony J. Recupero sold 3,311 shares of SI-BONE stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the sale, the insider now owns 284,555 shares of the company's stock, valued at $4,026,453.25. The trade was a 1.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total value of $44,229.92. Following the completion of the transaction, the senior vice president now directly owns 244,878 shares in the company, valued at approximately $3,462,574.92. This represents a 1.26 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 7,112 shares of company stock valued at $101,275. 3.90% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on SIBN shares. Truist Financial reiterated a "buy" rating and issued a $22.00 price target (up previously from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Needham & Company LLC upped their target price on shares of SI-BONE from $20.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of SI-BONE in a research report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $24.40.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.